# Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma

> **NCT06093061** · PHASE2 · RECRUITING · sponsor: **National Cancer Centre, Singapore** · enrollment: 53 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **COMBINATION_PRODUCT:** CCRT with Maintenance Tislelizumab and Metronomic Capecitabine

## Key facts

- **NCT ID:** NCT06093061
- **Lead sponsor:** National Cancer Centre, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-03
- **Primary completion:** 2028-10
- **Final completion:** 2029-10
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-04-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06093061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06093061, "Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06093061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*